NCT06349213 Uncovering the Cognitive and Neural Mechanisms Underlying Cognitive Time
| NCT ID | NCT06349213 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France |
| Condition | Healthy Aging |
| Study Type | OBSERVATIONAL |
| Enrollment | 130 participants |
| Start Date | 2024-11-20 |
| Primary Completion | 2026-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 130 participants in total. It began in 2024-11-20 with a primary completion date of 2026-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Time processing, the ability to process and encode temporal information, is essential for cognitive functioning and for a large number of daily life activities. In particular, the processing of durations of several seconds is central to cognition, impaired in several pathologies, and has been associated with cognitive changes with advancing age. While behavioral studies have been conducted to specify the neural bases of temporal cognition and their association with other cognitive functions, the mechanisms underlying age-related changes, and individual differences, remain unknown. The project will characterize ageing effects on timing mechanisms and their neural underpinnings. Building on recent advances from neuroscience and age-related cognitive changes, the project focuses on the precision of duration processing, that declines with age, and the associated neural bases. Participants will perform a duration judgement task while (a) electroencephalography, and (b) functional magnetic resonance imaging activity are simultaneously recorded to investigate age effects on structural and functional network connectivity. In addition, striatal dopamine will be measured using a FDOPA PETscan. Evaluation of other temporal cognition processes and general cognition will also be performed. This combination offers a unique opportunity to accurately specifying the neurophysiological underpinning of aging effects on time processing changes. This project will further our understanding of the variability of cognitive performance with advancing age, and contribute to identifying new measures of temporal impairments.
Eligibility Criteria
Inclusion Criteria: 1. Membership of a social security scheme or beneficiary of such a scheme. 2. At least 7 years' schooling. 3. Acceptance and signature of the informed consent form 4. Fluency in French (as assessed by the project leader) 5. Age between 20 and 35 years inclusive for young healthy subjects, and between 60 and 85 years inclusive for elderly healthy subjects. 6. Effective contraception for women of childbearing age: Contraception will be considered effective from the moment the participant declares taking an oral contraceptive, the presence of an IUD, diaphragm or contraceptive implant, or the performance of a tubal ligation or sterilisation. 7. Absence of global cognitive deficit attested by a score on the MOCA scale greater than or equal to 26/30. Exclusion Criteria: 1. Persons under guardianship, curators or safeguard of justice. 2. Pregnant women, women in labor and nursing mothers 3. Chronic neurological conditions 4. Uncorrected visual difficulties 5. Encephalitis 6. Endocrine or liver disease 7. History of head trauma with loss of consciousness lasting more than one hour 8. History of cancer in the last 5 years, with the exception of squamous cell carcinoma of the skin 9. Presence or history of chronic alcoholism or drug addiction 10. Presence of clinically significant major psychiatric disorders (according to DSM-IV-TR criteria) or symptoms that could affect the participant's ability to complete the research. 11. Use of medications that may modulate the dopaminergic system (psychotropic, with the exception of sleeping pills or occasional use of anxiolytics, as decided by the principal investigator). 12. Contraindications to MRI examination (pregnancy; pacemaker or neurosensory stimulator or implantable defibrillator; clip on an aneurysm or clip on a vascular malformation of the brain; intraocular or cerebral ferromagnetic foreign body; prosthesis or mobilizable ferromagnetic metal object or splinter; cochlear implant ; peripheral stimulator; neurosurgical ventriculoperitoneal shunt valves; permanent eyelid or lip make-up; jewelry or piercing that cannot be removed; certain tattoos depending on the type of ink, size and location; automated injection devices such as insulin pumps, blood glucose sensors, claustrophobia). 13. Radiotracer contraindications: Hypersensitivity to product excipients, chronic alcoholism, kidney disease. 14. Participation in research involving exposure to ionizing radiation (nuclear medicine or radiology examinations) in the year preceding inclusion or during a period of exclusion from other research.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06349213 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 85 Years, studying Healthy Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06349213 currently recruiting?
Yes, NCT06349213 is actively recruiting participants. Contact the research team at thomas.hinault@inserm.fr for enrollment information.
Where is the NCT06349213 trial being conducted?
This trial is being conducted at Caen, France.
Who is sponsoring the NCT06349213 clinical trial?
NCT06349213 is sponsored by Institut National de la Santé Et de la Recherche Médicale, France. The trial plans to enroll 130 participants.